Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 30341058

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2019 Jan 10
First author
Kusumoto S

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2019 Jan 10;133(2):104-106. doi: 10.1182/blood-2018-11-882167.
    note
    Source null
    related pmid
    30630846
    relationship
    Comment in

Authors and identifiers

  1. name
    Kusumoto S
    type
    Author
  2. name
    Arcaini L
    type
    Author
  3. name
    Hong X
    type
    Author
  4. name
    Jin J
    type
    Author
  5. name
    Kim WS
    type
    Author
  6. name
    Kwong YL
    type
    Author
  7. name
    Peters MG
    type
    Author
  8. name
    Tanaka Y
    type
    Author
  9. name
    Zelenetz AD
    type
    Author
  10. name
    Kuriki H
    type
    Author
  11. name
    Fingerle-Rowson G
    type
    Author
  12. name
    Nielsen T
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kusumoto S
    type
    Author
  2. name
    Arcaini L
    type
    Author
  3. name
    Hong X
    type
    Author
  4. name
    Jin J
    type
    Author
  5. name
    Kim WS
    type
    Author
  6. name
    Kwong YL
    type
    Author
  7. name
    Peters MG
    type
    Author
  8. name
    Tanaka Y
    type
    Author
  9. name
    Zelenetz AD
    type
    Author
  10. name
    Kuriki H
    type
    Author
  11. name
    Fingerle-Rowson G
    type
    Author
  12. name
    Nielsen T
    type
    Author
bibliography ids
  1. nci-bib-45de5b1e5fb44f4e012f2980
book metadata
content sha256
a3d142d7d1be274e4050c7b3c583598f0a811a9569d7b4f1c533c8f15b1b5088
document type
citation
dois
  1. 10.1182/blood-2018-04-848044
electronic publication date
display
2018 Oct 19
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:30341058
immutable id
pubmed:30341058@a3d142d7d1be274e4050c7b3c583598f0a811a9569d7b4f1c533c8f15b1b5088
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
2
name
Blood
nlm unique id
7603509
pages
137-146
volume
133
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2019 Jan 10;133(2):104-106. doi: 10.1182/blood-2018-11-882167.
    note
    Source null
    related pmid
    30630846
    relationship
    Comment in
outcomes validated
false
pmid
30341058
provenance
batch id
438b2803888025c6cf56
provider
NCBI PubMed ESummary
record sha256
5bd308f12f5f1c9eb4c2d5a8d4aff98381ad6bff945268f340b9d373fa3ddfc1
response sha256
0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
retrieved at
2026-09-09T23:47:36.359220+00:00
publication date
display
2019 Jan 10
precision
day
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30341058/
title
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Preserved source evidence · Independent clinical review pending · Not medical advice